Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome

  • Technology appraisal guidance
  • TA335
  • Published: 
Download guidance (PDF)

8 Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by the School of Health and Related Research (ScHARR), The University of Sheffield:

  • Pandor A, Pollard D, Stevenson M, et al., Rivaroxaban for the prevention of adverse outcomes in patients after the acute management of acute coronary syndrome: a single technology appraisal (August 2014)

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I. Company:

  • Bayer (rivaroxaban)

II. Professional/specialist and patient/carer groups:

  • British Heart Foundation

  • Pumping Marvellous

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians

  • United Kingdom Clinical Pharmacy Association

III. Other consultees:

  • Department of Health

  • NHS England

  • Welsh Government

IV. Commentator organisations (did not provide written evidence and without the right of appeal):

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • Medicines and Healthcare products Regulatory Agency

  • National Institute for Health Research Health Technology Assessment Programme

  • School of Health and Related Research Sheffield (ScHARR)

C. The following individuals were selected from clinical expert and patient expert nominations from the consultees and commentators. They gave their expert personal view on rivaroxaban by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr James Cotton, Consultant Cardiologist, nominated by organisation representing British Cardiovascular Intervention Society – clinical expert

  • Professor Carlo Di Mario, Consultant Cardiologist, nominated by organisation representing Bayer – clinical expert

  • Mr Nick Hartshorne‑Evans, nominated by organisation representing Pumping Marvellous Foundation – patient expert

  • Ms Jayne Knowles‑Smith, nominated by organisation representing Pumping Marvellous Foundation – patient expert

D. Representatives from the following company attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Bayer